We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




HbA1c Levels May Help Predict CF-Related Diabetes

By LabMedica International staff writers
Posted on 14 Mar 2019
Cystic fibrosis-related diabetes (CFRD) shares some features with both type 1 and type 2 diabetes. More...
In people with cystic fibrosis (CF), the thick, sticky mucus that is characteristic of the disease causes scarring of the pancreas.

People with CFRD may not experience any symptoms. Some diabetes symptoms are similar to other CF symptoms that they may already have. Many people with CFRD do not know they have CFRD until they are tested for diabetes.

Medical specialists at the University Hospital Llandough (Llandough, UK) conducted a seven‐year retrospective longitudinal study in 50 adults (42% women; mean age, 26 years) with CF, comparing oral glucose tolerance test results (OGTT) with HbA1c values in predicting the development of CFRD. Retinal screening data were also compared with HbA1c measurements to assess microvascular outcome. Participants were followed between 2006 and 2012 and had fasting plasma glucose and 2-hour postprandial glucose levels measured by OGTT and HbA1c levels measured by high-performance liquid chromatography.

The team created a receiver-operating characteristic (ROC) curve to measure the association between HbA1c and OGTT with diabetes development. HbA1c had an area under the fitted ROC curve of 0.76 in 2006 and a larger AUC when used as a baseline variable in comparison with fasting blood glucose (FPG), which suggested that HbA1c level is closely associated with the development of CFRD, using OGTT as the outcome diagnostic test. In addition, abnormal OGTT results were more likely for participants with HbA1c levels of 37 mmol/mol or more than those with lower levels during the seven years (hazard ratio [HR] = 3.49). The investigators also found that 19/43 participants with CFRD developed diabetic retinopathy between 2010 and 2012 and that HbA1c levels were higher for these participants (mean HbA1c = 68 mmol/mol) than those without diabetic retinopathy (mean HbA1c = 54 mmol/mol).

The authors concluded the present findings suggest that HbA1c could also be used in assessing individuals at risk of developing cystic fibrosis-related diabetes, in addition to the OGTT, as more participants who had mean HbA1c levels of 37 mmol/mol or more developed dysglycemia than those with lower levels during follow-up. The study was published on January 30, 2019, in the journal Diabetic Medicine.

Related Links:
University Hospital Llandough


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.